Akouos announced two key senior leadership appointments. Morgan Molloy joins the team as chief corporate development officer, and Karoline Shair, Ph.D., J.D., joins the team as senior vice president, general counsel and corporate secretary. Morgan Molloy joins Akouos with more than 25 years of broad commercial and operational leadership experience in the biopharmaceutical industry. Most recently, he served as chief commercial officer at Enzyvant, Inc., where he led all aspects of the commercial strategy for the company’s rare disease portfolio. Prior to Enzyvant, he served as the head of U.S. commercial for Spark Therapeutics. In this role, he was responsible for the development of commercial strategy and planning for Spark’s gene therapy programs. Mr. Molloy has also held a variety of operational and commercial roles at Sanofi-Genzyme, including vice president, global disease lead of the Fabry disease franchise. Before Sanofi-Genzyme, he served in multiple commercial leadership roles of increasing responsibility at Biogen. Karoline Shair brings to Akouos more than 20 years of senior leadership and global legal expertise in the biotechnology and pharmaceutical industries. Most recently, she was the vice president, head counsel intellectual property (IP) program portfolio at Biogen, where she led the company’s global IP portfolio strategy, IP diligence and transactions for business development and M&A opportunities. Prior to Biogen, Dr. Shair was vice president legal, chief intellectual property counsel and corporate secretary at FORMA Therapeutics, where she was responsible for building the legal department and providing strategic counsel on all legal matters. Dr. Shair also held leadership roles at Millennium Pharmaceuticals and Takeda Pharmaceuticals, including vice president, IP region head, where she led IP strategy, litigation and transactions for the global oncology therapeutic area and business unit. Dr. Shair has also practiced law at Vertex Pharmaceuticals and Choate, Hall & Stewart.